Publications
Timeline
- Abstracts/Posters
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
Spigel DR, Westeel V, Anderson IC, et al. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. Lancet Respir Med . Published online June 24, 2025. doi:10.1016/S2213-2600(25)00213-9
- Publication
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
Kratz, J. R., et al. (2025). Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. The Lancet Respiratory Medicine , 13 (7), E19-E20.
- Abstracts/Posters
Molecular recurrence risk profiles in patients with early-stage NSCLC: Current standard of care compared to a prognostic and predictive 14-gene expression assay
Hufham J, Aversano J, Doleshal M, Harrington D. (2022, September) Molecular recurrence risk profiles in patients with early-stage NSCLC: Current standard of care compared to a prognostic and predictive 14-gene expression assay. Abstract presented at 2022 North American Conference on Lung Cancer.
- Publication
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy
Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, et al. (2021). Molecular Risk Stratification is Independent of EGRF Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy. Clin Lung Cancer , 22:587-595.
- Abstracts/Posters
Characterization of clinicopathologic features and molecular recurrence risk profiles in patients with early-stage NSCLC
Riordan S, Doleshal M, Orck J, Harrington D. (2021, January) Characterization of clinicopathologic features and molecular recurrence risk profiles in patients with early-stage NSCLC. Abstract presented at 2020 World Conference on Lung Cancer.
- Abstracts/Posters
Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy
Woodard G, Kratz J, Haro G, Gubens M, Blakely C, et al. (2020, October) Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Abstract presented at 2020 North America Conference on Lung Cancer.
- Abstracts/Posters
The potential of a CLIA-certified prognostic/predictive molecular test to address the rising costs of non-small cell lung cancer
Mann M, Jablons D, O’Day K, Su W, Sundar P. (2020, May). The potential of a CLIA-certified prognostic/predictive molecular test to address the rising costs of non-small cell lung cancer. Journal of Clinical Oncology. 38 supplement:e21671.
- Abstracts/Posters
Everybody must get scanned? Molecular risk stratification may limit the need for CT surveillance following surgical resection of early-stage non-squamous, non-small cell lung cancer
Hamilton B, Haro G, Woodard G, Sheu B, Kratz J, et al. (2020, May) Everybody must get scanned? Molecular risk stratification may limit the need for CT surveillance following surgical resection of early-stage non-squamous, non-small cell lung cancer. Abstract presented at ATS International Conference, Philadelphia, PA.
- Publication
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. (2019) Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer. JAMA Network Open 2:e1917062
- Publication
Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging
Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, et al. (2019) Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. Journal of Thoracic Oncology 14:1223.
- Publication
Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58.
- Abstracts/Posters
Expanded data confirm molecular testing identifies lung adenocarcinoma patients, including stage IA, who benefit from adjuvant chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, et al. (2018) Expanded data confirm molecular testing identifies lung adenocarcinoma patients, including stage IA, who benefit from adjuvant chemotherapy. Journal of Thoracic Oncology. 12:s835.
- Abstracts/Posters
Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging
Haro G, Kratz J, Cook N, He J, Van Den Eeden G, et al. (2018) Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. Journal of Thoracic Oncology. 13:s919.
- Abstracts/Posters
Adjuvant chemotherapy decisions based on molecular risk status improves outcomes in early stage, non-small cell lung cancer
Woodard G, Crockard J, Zoon-Besselink C, Kratz J, Gubens M, et al. (2017) Adjuvant chemotherapy decisions based on molecular risk status improves outcomes in early stage, non-small cell lung cancer. Journal of Thoracic Oncology. 12:s320.
- Publication
The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer
Dormady S, Broder MS, Putcha GV, Dumanois RH, DeCristofaro AH, et al. (2015) The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol 20:59.
- Publication
Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small cell lung cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, et al. (2014) Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small cell lung cancer. Clinical Lung Cancer 15:426.
- Publication
Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer
Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, et al. (2013) Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagnostic Molecular Pathology 22:65.
- Publication
A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors
Kratz JR, Van Den Eeden SK, He J, Jablons DM, Mann MJ. (2012) A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA 308:1629.
- Publication
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies
Kratz JR, He J, Van Den Eeden SK, Zhu Z, Gao W, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
